Literature DB >> 22608068

Buspirone: what is it all about?

C Loane1, M Politis.   

Abstract

Buspirone is an anxiolytic drug and is a partial agonist for the serotonin 5-HT(1A) receptors as well as possessing low affinity and is an antagonist for the dopamine D(2) autoreceptors, with some evidence of a weak affinity to 5-HT(2) receptors. The underlying mechanism of action of buspirone is not clear; however it is thought that its main pharmacology is mediated via the 5-HT(1A) receptors. Initially developed for use in the treatment of generalised anxiety disorder, it appears that buspirone may be useful in various other neurological and psychiatric disorders, such as attenuating side effects of Parkinson's disease therapy, ataxia, depression, social phobia, and behaviour disturbances following brain injury, and those accompanying Alzheimer's disease, dementia and attention deficit disorder. Considering the potential of this drug to be included in the management of many conditions, thorough and controlled studies are required to elucidate the exact mechanism of action. This review will consider the evidence so far for both the potential underlying mechanisms and its use in various conditions.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608068     DOI: 10.1016/j.brainres.2012.04.032

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  39 in total

1.  Pd-Catalyzed Synthesis of Piperazine Scaffolds Under Aerobic and Solvent-Free Conditions.

Authors:  Sean W Reilly; Robert H Mach
Journal:  Org Lett       Date:  2016-10-13       Impact factor: 6.005

Review 2.  The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

Authors:  Sheryl A Kingsberg; Anita H Clayton; James G Pfaus
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

Review 3.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

4.  Human motoneurone excitability is depressed by activation of serotonin 1A receptors with buspirone.

Authors:  Jessica M D'Amico; Annie A Butler; Martin E Héroux; Florence Cotel; Jean-François M Perrier; Jane E Butler; Simon C Gandevia; Janet L Taylor
Journal:  J Physiol       Date:  2016-12-17       Impact factor: 5.182

5.  Buspirone, a new drug for the management of patients with ineffective esophageal motility?

Authors:  Charlotte Scheerens; Jan Tack; Nathalie Rommel
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

6.  Developmental effects of serotonin 1A autoreceptors on anxiety and social behavior.

Authors:  Zoe R Donaldson; David A Piel; Tabia L Santos; Jesse Richardson-Jones; E David Leonardo; Sheryl G Beck; Frances A Champagne; René Hen
Journal:  Neuropsychopharmacology       Date:  2013-08-02       Impact factor: 7.853

7.  Somatosensorimotor and Odor Modification, Along with Serotonergic Processes Underlying the Social Deficits in BTBR T+ Itpr3tf/J and BALB/cJ Mouse Models of Autism.

Authors:  Hiroyuki Arakawa
Journal:  Neuroscience       Date:  2020-02-13       Impact factor: 3.590

8.  Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

Authors:  D Lindenbach; N Palumbo; C Y Ostock; N Vilceus; M M Conti; C Bishop
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

9.  Buspirone reduces sexual risk-taking intent but not cocaine self-administration.

Authors:  B Levi Bolin; Joshua A Lile; Katherine R Marks; Joshua S Beckmann; Craig R Rush; William W Stoops
Journal:  Exp Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.157

10.  Anxiety and depression in Parkinson's disease.

Authors:  Atbin Djamshidian; Joseph H Friedman
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.